Technical corrections only. The diff updates cross-references and section numbers, specifically changing references from section 15 to section 14 throughout the bill. No substantive policy changes were made between v1 and v2.
Interagency Patent Coordination and Improvement Act of 2025
- Sponsor
- Sen. Durbin, Richard J. [D-IL]
- Committees
- Judiciary Committee (primary)
- Last action
- Apr 10, 2025
Bottom line
The bill aims to improve the quality and accuracy of pharmaceutical patent examinations by enhancing coordination and information exchange between the USPTO and FDA, with safeguards for confidential data.
What it actually does
This bill establishes an Interagency Task Force on Patents between the United States Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA). Its primary purpose is to facilitate information sharing and technical assistance between the two agencies regarding patents for human drugs and biological products. The task force will develop protocols for sharing confidential information, ensuring patent examiners have access to relevant FDA data for prior art assessment and accurate patent representations, while also assisting the FDA with its patent listing functions.
Proponents argue
Supporters argue that enhanced collaboration between the USPTO and FDA is crucial for improving the quality of pharmaceutical patents. They contend that better access to FDA's scientific and regulatory information will allow patent examiners to more accurately assess prior art and the novelty of drug-related inventions, thereby reducing the issuance of weak or invalid patents. This, in turn, could foster innovation by ensuring only truly novel inventions are protected and potentially accelerate the availability of generic drugs by preventing unwarranted patent extensions.
Opponents contend
Critics might express concerns that increased information sharing, even with safeguards, could inadvertently expose proprietary or confidential commercial information, potentially undermining the competitive advantage of pharmaceutical innovators. They might also argue that adding a new interagency task force and associated protocols could introduce bureaucratic delays into both patent examination and drug approval processes, rather than streamlining them. Some may also question the necessity, arguing existing mechanisms are sufficient or that the scope of information sharing could be too broad.
The bill is relatively short and clearly structured, making it accessible for an informed reader to understand its core provisions within the estimated reading time.
Section 4(a)(2), adding 35 U.S.C. 14(a)
Establishment of Interagency Task Force on Patents
This provision formally establishes the Interagency Task Force on Patents, bringing together the USPTO and FDA. Its mandate is to coordinate efforts, share information, and provide technical assistance concerning patents for human drugs and biological products. This aims to ensure consistency and accuracy in how patent applications and related information are handled across both agencies.
Supporters argue
Proponents argue that a dedicated task force is essential to formalize and enhance interagency communication, which is currently ad hoc. This structured approach will lead to more consistent and informed decisions regarding pharmaceutical patents, benefiting both agencies and the public by ensuring patent quality.
Critics contend
No specific opposition is typically raised against the mere establishment of an interagency task force, though concerns may arise regarding its operational scope or potential for bureaucratic overhead.
Tradeoffs
The primary tension is between the desire for enhanced interagency coordination to improve patent quality and the potential for increased administrative burden or delays in establishing and operating such a formal body.
Section 4(a)(2), adding 35 U.S.C. 14(d)(3)(A)
USPTO Access to FDA Information for Patent Examination
This provision mandates a process for the USPTO Director to request, and the FDA Commissioner to provide, information relevant to patent examination for human drugs and biological products. This includes publicly available information about drug approvals and, critically, appropriate access for patent examiners to non-public product application, approval, patent, and labeling information or communications between FDA and sponsors, when necessary for USPTO responsibilities like assessing prior art or ensuring accurate representations.
Section 4(a)(2), adding 35 U.S.C. 14(f)
Confidentiality Protocols and Safeguards
This section outlines strict confidentiality requirements for information shared between the USPTO and FDA. It allows for the sharing of confidential records but mandates that such information remains subject to the same protections as if held by the FDA. Crucially, the task force must establish protocols requiring 30 days' notice to a drug sponsor before their confidential information is shared, allowing for consultation. The USPTO Director must also keep shared confidential information separate from pending patent applications and establish procedures to prevent inadvertent disclosure, with the task force identifying remedies for any potential injury from disclosure.
This provision grants patent examiners 'appropriate access' to 'relevant sources of product application, approval, patent, and labeling information or communications between the Food and Drug Administration and the human drug or biological product sponsors that may not currently be subject to public disclosure.' This access is specifically for ensuring accurate representations and assessing whether the claimed invention was 'on sale before the effective filing date of the claimed invention, as described in section 102(a)(1)'.
Section 4(a)(2), adding 35 U.S.C. 14(d)(3)(A)(ii)
Why it matters:The specific reference to 35 U.S.C. 102(a)(1) is standard legislative drafting for precision in legal amendments. The detailed description of information access is necessary for clarity but can make the provision dense.
Case for: Supporters argue that this specific grant of access to non-public FDA communications is vital for patent examiners to thoroughly evaluate prior art and prevent the issuance of patents for inventions that were already commercially available or disclosed, thus strengthening patent quality and preventing 'evergreening' strategies.
Case against: Critics might argue that allowing access to non-public communications, even for specific purposes, represents a significant expansion of government access to proprietary information. They may worry about the precedent this sets and the potential for misinterpretation or misuse of sensitive data, despite the confidentiality protocols.
Estimated impact: Potentially significant impact on the rigor of patent examination for pharmaceutical products, leading to fewer questionable patents being granted and potentially influencing market entry for generic drugs.
The confidentiality protocols established by the task force must provide for a 30-day notice to the sponsor of a human drug or biological product before any confidential information relating to that product is shared between the agencies, allowing for consultation. Furthermore, the task force is required to identify appropriate remedies for any potential injury suffered when confidential information is made available, including inadvertently, through this sharing.
Section 4(a)(2), adding 35 U.S.C. 14(f)(2)(B)(i) and (C)
Why it matters:These are specific operational details necessary for the implementation of the confidentiality framework, rather than high-level policy statements. Their placement within the detailed protocol requirements is logical for legislative drafting.
Case for: Supporters argue these provisions are critical safeguards, providing due process for companies whose confidential information might be shared and ensuring that mechanisms exist to address any harm from accidental disclosures. This builds trust and ensures fairness.
Case against: Critics might argue that while notice and remedies are positive, they do not fully mitigate the risk of disclosure or the potential damage to proprietary information, especially if the remedies are difficult to enforce or insufficient to cover actual losses. Some might also see the 30-day notice period as a potential delay in the information-sharing process.
Estimated impact: Provides a crucial layer of protection for pharmaceutical companies' confidential data and establishes a framework for addressing potential harm, influencing industry's comfort level with the information-sharing initiative.